Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial

Aminah Jatoi, James Egner, Charles Lawrence Loprinzi, Jeff A Sloan, Paul J. Novotny, Shaker R. Dakhil, James A. Mailliard, George G. Klee, James E. Krook

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. Methods: Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. Results: A total of 118 patients participated. At baseline, 99%, 54%, and 47% of patients' samples had undetectable IL-1β, TNFα, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. Conclusion: Serum concentrations of IL-1β, TNFα, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.

Original languageEnglish (US)
Pages (from-to)640-644
Number of pages5
JournalSupportive Care in Cancer
Volume12
Issue number9
DOIs
StatePublished - Sep 2004

Fingerprint

Anorexia
Weight Loss
Cytokines
Interleukin-6
Serum
Interleukin-1beta
Neoplasms
Tumor Necrosis Factor-alpha
Appetite
Weights and Measures
Survival

Keywords

  • Cancer anorexia/weight loss syndrome
  • Cytokines
  • Interleukin-1 beta
  • Interleukin-6
  • Tumor necrosis factor alpha

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. / Jatoi, Aminah; Egner, James; Loprinzi, Charles Lawrence; Sloan, Jeff A; Novotny, Paul J.; Dakhil, Shaker R.; Mailliard, James A.; Klee, George G.; Krook, James E.

In: Supportive Care in Cancer, Vol. 12, No. 9, 09.2004, p. 640-644.

Research output: Contribution to journalArticle

Jatoi, Aminah ; Egner, James ; Loprinzi, Charles Lawrence ; Sloan, Jeff A ; Novotny, Paul J. ; Dakhil, Shaker R. ; Mailliard, James A. ; Klee, George G. ; Krook, James E. / Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. In: Supportive Care in Cancer. 2004 ; Vol. 12, No. 9. pp. 640-644.
@article{badbdcf7c0714b1488c2d3518ad78d09,
title = "Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial",
abstract = "Background: Interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. Methods: Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. Results: A total of 118 patients participated. At baseline, 99{\%}, 54{\%}, and 47{\%} of patients' samples had undetectable IL-1β, TNFα, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. Conclusion: Serum concentrations of IL-1β, TNFα, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.",
keywords = "Cancer anorexia/weight loss syndrome, Cytokines, Interleukin-1 beta, Interleukin-6, Tumor necrosis factor alpha",
author = "Aminah Jatoi and James Egner and Loprinzi, {Charles Lawrence} and Sloan, {Jeff A} and Novotny, {Paul J.} and Dakhil, {Shaker R.} and Mailliard, {James A.} and Klee, {George G.} and Krook, {James E.}",
year = "2004",
month = "9",
doi = "10.1007/s00520-004-0624-3",
language = "English (US)",
volume = "12",
pages = "640--644",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial

AU - Jatoi, Aminah

AU - Egner, James

AU - Loprinzi, Charles Lawrence

AU - Sloan, Jeff A

AU - Novotny, Paul J.

AU - Dakhil, Shaker R.

AU - Mailliard, James A.

AU - Klee, George G.

AU - Krook, James E.

PY - 2004/9

Y1 - 2004/9

N2 - Background: Interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. Methods: Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. Results: A total of 118 patients participated. At baseline, 99%, 54%, and 47% of patients' samples had undetectable IL-1β, TNFα, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. Conclusion: Serum concentrations of IL-1β, TNFα, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.

AB - Background: Interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. Methods: Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. Results: A total of 118 patients participated. At baseline, 99%, 54%, and 47% of patients' samples had undetectable IL-1β, TNFα, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. Conclusion: Serum concentrations of IL-1β, TNFα, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.

KW - Cancer anorexia/weight loss syndrome

KW - Cytokines

KW - Interleukin-1 beta

KW - Interleukin-6

KW - Tumor necrosis factor alpha

UR - http://www.scopus.com/inward/record.url?scp=4644301742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644301742&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0624-3

DO - 10.1007/s00520-004-0624-3

M3 - Article

C2 - 15278681

AN - SCOPUS:4644301742

VL - 12

SP - 640

EP - 644

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 9

ER -